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Abstract
Background: The identification of drug-target interactions (DTI) is a costly and time-consuming step in drug
discovery and design. Computational methods capable of predicting reliable DTI play an important role in the field.
Algorithms may aim to design new therapies based on a single approved drug or a combination of them.
Recently, recommendation methods relying on network-based inference in connection with knowledge coming
from the specific domain have been proposed.
Description: Here we propose a web-based interface to the DT-Hybrid algorithm, which applies a recommendation
technique based on bipartite network projection implementing resources transfer within the network. This
technique combined with domain-specific knowledge expressing drugs and targets similarity is used to compute
recommendations for each drug. Our web interface allows the users: (i) to browse all the predictions inferred by
the algorithm; (ii) to upload their custom data on which they wish to obtain a prediction through a DT-Hybrid
based pipeline; (iii) to help in the early stages of drug combinations, repositioning, substitution, or resistance
studies by finding drugs that can act simultaneously on multiple targets in a multi-pathway environment. Our
system is periodically synchronized with DrugBank and updated accordingly. The website is free, open to all users,
and available at http://alpha.dmi.unict.it/dtweb/.
Conclusions: Our web interface allows users to search and visualize information on drugs and targets eventually
providing their own data to compute a list of predictions. The user can visualize information about the
characteristics of each drug, a list of predicted and validated targets, associated enzymes and transporters. A table
containing key information and GO classification allows the users to perform their own analysis on our data.
A special interface for data submission allows the execution of a pipeline, based on DT-Hybrid, predicting new
targets with the corresponding p-values expressing the reliability of each group of predictions. Finally, It is also
possible to specify a list of genes tracking down all the drugs that may have an indirect influence on them based
on a multi-drug, multi-target, multi-pathway analysis, which aims to discover drugs for future follow-up studies.
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Background
In the last decades, pharmacology and therapeutic fields
have encountered several development shortcomings
due to prohibitive clinical costs related to novel drug
discovery. The development of a new molecular entity is
typically based on the process of discovering a new drug
by modifying an existing one [1]. Recent trends in the
pharmacogenomics area are going to exploit data
mining and bioinformatics approaches, such as those
based on drugs similarity, in connection with biological
networks analysis. In Phatak et al. [2], a computational
method for drug repositioning differs from previous
similarity-based approaches since it combines chemical
drug structures and drug target information computing
similarity of drug target profiles via a bipartite-graph
based approach. Bipartite graphs can also be used to
provide a drug-target network for assessing the similar-
ity between different disease inhibitors based on the
connection to other compounds and targets. In this
case, classical structure-based drug design and chemical-
genomic similarity methods are combined with molecu-
lar graph theories. Another example of network based
drug study is shown in Iorio et al. [3], where drug mode
of action and drug repositioning are assessed using
available gene expression profiles [4] to build a drug-
drug network. The Connectivity Map databases [4] is a
comprehensive reference catalog of genome-wide
expression data from cultured human cells perturbed
with many chemicals and genetic reagents, to connect
human diseases with the genes that may cause them
and drugs that can treat them. Literature-mining studies
show that a large majority of new drugs bind to targets
in some way related to a previously existing one [5-7]. A
taxonomy and a comprehensive survey of new drugs
discovery is contained in Csermely et al. [8].
An important role in the development of new drugs is
given by the methods predicting drug-target interactions
(DTI). Traditionally researchers have focused their atten-
tion on the development of drugs acting only on a speci-
fic protein family. On the other hand the more recent
poly-pharmacology approach [9] combines actions of
drugs and related multiple targets. The knowledge of
these targets is fundamental to find out alternative appli-
cations (drug repositioning) as well as to identify side
effects [10,11]. Despite all such efforts, today many inter-
actions are still unknown and in situ experiments are too
costly and time-consuming to be used as the sole
strategy.
Various techniques to solve such a problem have been
proposed [6,12-16]. In particular, the naive application
[17] of the recommendation algorithm developed in Zhou
et al. [18] has shown extremely promising results. In
Alaimo et al. [19] an extension of the above method with
the addition of domain-tuned knowledge led to the
definition of the DT-Hybrid algorithm, combining bipar-
tite networks projection and network resources transfer.
The process is driven by 2D drug structural similarity, and
target sequential similarity. The basic idea is that structu-
rally similar drugs tend to have analogous behavior in
similar proteins.
Another DTI prediction software is STITCH 4.0
[20-23]. It is a database of multi-species protein-chemi-
cal interactions, which, not only integrates many experi-
mentally validated and manually curated data sources,
but also provides a technique to compute predictions
based on text-mining in research articles and analysis of
chemical structures. The database combines this infor-
mation to get an overall score that indicates the degree
of confidence of the interaction. However, it can only be
applied to the data in their internal database, and users
can only search within such data or download the entire
list of predictions, rather than providing their own com-
pounds and/or proteins. Moreover, STITCH 4.0 does
not compute drugs targeting combinations.
In addition, nowadays, research has been focused on
new strategies exploiting metabolic and signaling net-
works since they show properties for the treatment of
infection and cancer diseases. Graph searching algo-
rithms help to exploit such data [24-29]. A metabolic
pathway describes a series of chemical reactions occur-
ring within a cell, in which enzymes catalyze the modifi-
cation of an initial metabolite to form another product.
A pathway may include biochemical reactions, complex
assembly, transport events, catalysis events and physical
interactions involving metabolites, namely proteins,
DNA, RNA, small molecules and complexes. The set of
metabolic pathways forms the metabolic network of a
cell, which is part of its complex system, together with
signaling pathways, representing the response to exter-
nal signals, and other physical processes. Enzymes cata-
lyzing a single reaction are usually essential [30],
however related metabolites are frequently involved in sev-
eral different pathways. Consequently, analyzing metabolic
networks helps to identify interesting entities, such as:
metabolites used as disease biomarkers [31,32]; or choke
points (reactions that consume or produce a certain meta-
bolite) [33,34], whose inhibition may cause lethal deficien-
cies or toxic accumulation of metabolites. Motivated by
the success of manual pathway analysis, a pathway-based
approach was proposed in Li et al. [35-37] where a causal
drug-to-disease network is built by taking advantage of
expert-curated biological knowledge including drug tar-
gets, pathways and disease downstream genes. Since,
many human diseases cause metabolic deficiencies, the
enzymes involved in such essential reactions can be con-
sidered promising drug targets [38-41]. Due to the com-
plexity of diseases, the development of multi-target drugs
[42,43] or drug combinations may be considered crucial.
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The choke point analysis, the comparison of metabolic
networks of pathogenic and non-pathogenic strains and
the load point analysis, may improve effective combina-
tions prediction. These commonly consist in the identifi-
cation of nodes having a high ratio of incident k-shortest
paths [44,45]. On the other hand, it has been shown that
co-targeting of crucial pathway points [46-49] is efficient
against drug resistances both in anti-infective [50] and
anti-cancer [51,52] strategies. Two relevant examples are
RAS and Survivin associated diseases.
The RAS oncogenic mutations occur in human cancer
quite frequently [53]. Therapeutic approaches based on
the inhibition of RAS-mediated signalling have resulted
ineffectively mainly due to the drug’s toxicity. On the
other hand, mutations of RAS, cause high levels of drug
resistance. To overcome such shortcomings, Nussinov
et al. [54] suggests an approach, inspired by Holzapfel
et al. [55], based on drug combinations on parallel
pathways.
The Survivin protein is linked to multiple pathways of
cellular homeostasis [56]. These seem to confer to can-
cer cells a great plasticity, proliferation capability and
resistance to death. Moreover, a large number of mole-
cules, regulators, transcriptional networks and modifiers
are directly or indirectly involved in Survivin related
networks. Therefore, approaches considering Survivin in
isolation and based on single-protein inhibitors [57]
appear to be unsatisfactory. The development of drugs
based on pathways inhibitors [58] exploiting the connec-
tivity maps of Survivin to multiple signaling circuits [4]
may result in a more effective approach.
An important application of biological network analysis
concerns drug repositioning, a central task in new treat-
ments discovery [13,14,59,60]. In Jahchan et al. [61] and
Smith et al. [62], a pathway enrichment analysis in com-
bination with gene expression profiles to explore new
applications of existing drugs has been exploited. In Pan
et al. [63], sixteen FDA-approved drugs were studied in
order to understand their clinical functions through
pathway analysis. Targets interacting or affected by the
investigated drugs were extracted by mining public data-
bases. Pathways having a co-occurrence of such targets
were ranked through a p-value. Although directly and
indirectly correlated drug targets were identified, impor-
tant limitations arose due to relevant pathway retrieval
and unknown targets finding.
In this paper, we propose DT-Web a software resource
accessible via web at [64], using known sources, such as
DrugBank [65-67] and PathwayCommons [68], in con-
nection with DT-Hybrid [19] recommendation algorithm.
It implements two analysis tools relying on networks: the
first one uses a bipartite drug-target interaction network
to predict novel high confidence DTIs, while the second
one uses a multi-drug, multi-target, multi-pathway
approach to guide the early stages of experimental analy-
sis in drug combinations studies. In fact, even if
researches can relay on public-domain databases of drug
combination references, such as Liu et al. [69], there is
still a lack of systematic computational approaches, and
often several possible drug combinations are disclaimed
by expert knowledge and verified via clinical trials.
Motivated by the success of network-based approaches,
our multi-purpose pathway analysis aims to provide a
limited set of candidate drugs both for drug repositioning
and combination, that can be directly evaluated by the
experts or combined with other methods.
Construction and content
The core of DT-Web has been developed in R and Java,
while its front-end consists of a web interface developed
in PHP with the backing of a MySQL database to store
persistent information. We collected only drugs, targets
and pathways for the Homo Sapiens species, and designed
our methodology accordingly. DT-Web offers two major
functionalities: (i) Drug-Target Interaction Prediction:
the integration of Drug-Bank with DT-Hybrid to provide
a comprehensive database of drugs, and their interactions
with proteins (targets, enzymes, transporters, or carriers),
either experimentally validated or predicted by DTI net-
work inference; (ii) Multi-Purpose Pathway Analysis: the
integration of DrugBank, DT-Hybrid, and Pathway-
Commons to aid the experimental phase in drug combi-
nation studies by searching for drugs simultaneously
acting on multiple targets.
Drug-target interaction prediction
In order to extend our knowledge base, predictions are
not limited to small molecules as in Alaimo et al. [19]
rather extended to biotech drugs using an appropriate
similarity measure based on their synthetic amino-acidic
sequence, if available.
In order to search for alternative predictions, DT-Web
allows uploading users own data. These may be processed
by a DT-Hybrid based pipeline. Statistically reliable results
will be returned. To guarantee data safety DT-Web assigns
to each prediction a random identifier, which is required
to retrieve the outcome. More precisely DT-Web actions
are summarized below:
Drug-target interactions prediction pipeline
Step 1. Through an appropriate form, users can upload a
DTI network equipped with a similarity matrix for each
pair of drugs and targets. DT-Hybrid tuning parameters
can be freely modified when this is requested.
Step 2. Users data are then checked to avoid incorrect
format, and the DT-Hybrid algorithm is applied to
obtain an initial list of predictions for each drug.
Step 3. Each target in the DTI network is mapped to
an Entrez identifier in order to annotate each node with
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a set of GO terms. Next, for each pair of terms, we
compute a similarity measure based on the node dis-
tance in the ontology DAG (Directed Acyclic Graph).
Notice that, such a DAG has been previously modified
to assign a value to each distance by connecting all the
root nodes in the original DAG to a new single dummy
root node.
Step 4. Finally, for each drug-target predicted pair, we
calculate a correlation measure as the maximum similar-
ity between ontological terms of validated targets and
predicted ones. Then, for each drug, we select subsets of
predicted targets with increasing minimum correlation,
computing, each time, a p-value using a hyper-geometric
distribution. Such subsets are filtered to return only
those minimizing p-values in each drug. The p-values
are computed as follows. Let M (i, j) be the j-th subset
of predicted targets for drug i, m be the number of tar-
gets and q (i, j) be the number of targets having a corre-
lation greater than the minimum computed in M (i, j).
The p-value, p (M (i, j)), is the probability of drawing by
chance |M (i, j)| = k (i, j) terms whose correlation is
greater than the observed minima. An hyper-geometric





















The p-value is used to provide a quality score to the
association between predicted and validated targets of a
single drug. No multiple test correction is applied, as
each reported p-value is considered independent from
the others.
Multi-purpose pathway analysis
The aim is to discover the minimal set of drug targets
that are able to affect a user-specified set of genes in a
multi-pathway environment. The distances among such
targets and user genes are limited to a given range in
order to minimize drug side effects. The set of validated
drug targets is extended with the DT-Hybrid predic-
tions, along with their score to give a measure of confi-
dence on each prediction.
The implemented pipeline has been divided into two
main phases. The first phase is performed off-line and
kept up-to-date whenever the DT-Web database is syn-
chronized with the latest version of DrugBank. The sec-
ond one is performed on-line and responses to the
pasting of a list of genes through the submission form.
Off-line database building pipeline
The calculation of a multi-pathway environment requires
huge computational resources and it is a time-consuming
task. Because of this, the construction of such an environ-
ment, consisting of merging the Homo sapiens metabolic
and signaling pathways contained in Reactome [70] and
PID [71], is done off-line through a proprietary Java mod-
ule, and stored in our database. The steps are the
following.
Step 1. We retrieve all pathways by downloading Bio-
Pax [72] level 3 XML files from the Pathway-Commons
web service, using PC2 [73] for the remote connection
to the public database.
Step 2. For each pathway, we first normalize entity
names if these exist (i.e. symbolic names for proteins,
such as BRCA1), otherwise we consider the BioPax
entity reference IDs.
Step 3. Subsequently, we collapse all nodes represent-
ing the same biological entity (protein sub-units or the
same protein in different cell locations) in a single node,
and we map them to the DrugBank database. Edge
directions are kept as they are in the input network,
except for those which connect a complex to a constitu-
ent protein that are made undirected.
Step 4. The entire set of retrieved pathways is merged
into a single global network by mapping nodes and
edges using their names and interaction types,
respectively.
Step 5. Finally, to control the combinatorial explosion
of such data, we store only directed shortest paths
between proteins that lie at a distance of, at most, 9
edges. Moreover, since a path could contain edges
belonging to different pathways, we decided to store for
each edge the list of pathways where it appears. We,
also, store the mapping to DrugBank database computed
at step 3.
Real-time prediction pipeline
Step 1. The user provides a list of genes (names in
HGNC format, or Uniprot Accession Number, or Entrez
Gene Id, or HGNC Id, or Ensembl Gene Id) through a
web interface. He can also set the ranges (min/max) for
distances between drug targets and user-provided genes
Direct-Indirect Range, or between each pair of drug tar-
gets Pair Range.
Step 2. Users’ data are thus filtered to remove all pro-
teins that are not present in our database. If the filtered
list is not empty, a search is performed in our multi-
pathway environment. The task selects all proteins
which are at distance within the Direct-Indirect Range
specified by the user.
Step 3. Each protein is then mapped in DrugBank, and
those targeted by at least one drug are selected as a pre-
liminary list of targets. Such a list is further filtered by
removing all pairs of targets which are outside of the
user-specified Pair Range.
Step 4. Next, by applying Chvatal et al. [74], we
quickly compute an approximation of the minimum
list of targets needed to reach all the user-specified
genes.
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Figure 1 DT-Web Search Example. Once the user provides a query (either a part of the name or the accession number of a drug/target), DT-
Web finds all the matching records in the internal database and returns them to the user in a page containing all the information requested. If
all the records are drugs, the user will also see, if available, their two-dimensional structures, and a list of all targets, enzymes, transporters,
carriers, and predicted targets, which have been computed through DT-Hybrid. Here user searched for DB00014
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Figure 2 DT-Web DTI Prediction Example. Once the user provides its own DTI network and, if possible, two similarity matrices for each pair of
drug and target, DT-Web applies the pipeline described above, after checking the validity of its input. At the end of such an operation, the user
will see a page containing a list of all the drugs for which a result was available, along with the corresponding measures of correlation and p-
value. By selecting one drug, the user will also see the list of all the predicted targets along with the scores assigned to each prediction by DT-
Hybrid.
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Step 5. Finally, the list of all targets calculated in step 3,
and each associated drug (experimentally validated or
predicted), is returned to the user, along with the mini-
mum set computed in step 4.
Utility and discussion
DT-Web is an effective and user-friendly system that
provides a web interface to visualize information on
drugs and predicted targets, and to simplify the earlier
experimental phases of drug combination studies by
applying a multi-drug, multi-target, multi-pathway
approach. All this is provided along with a constantly
updated database containing the main and most reli-
able information from DrugBank. In addition, with the
ability to upload their own data, our software does not
limit the user to use only pre-computed information.
We, also, compared the prediction scores generated by
STITCH 4.0 and DT-Web using a set of validated inter-
actions taken from DrugBank. The analysis showed that
the knowledge (i.e. experiments, structures, text-mining)
given as input to STITCH 4.0 generate a distribution of
scores which resulted bimodal and piled either on a low
or a up range. On the other hand, DT-Web, which pre-
dictions scores are based on structure similarities and
network inferences showed a Gaussian behavior. This dif-
ference is justifiable by both the kind of input knowledge
and inference methods the two systems use.
To use the integrated database, user provides one or
more keywords (see our website [64] for a more detailed
list of searchable information). The results will be
returned on a page, which, as described in Figure 1,
contains a list of the main information extracted from
DrugBank, experimentally verified targets, enzymes,
transporters, and carriers (along with papers providing
such experimental evidence), and the predictions calcu-
lated by DT-Hybrid.
To take advantage of the DTI prediction pipeline on
his own data, the user can choose the “Drug-Target
Interaction” job in the “Prediction Tools” menu of our
web interface. He will be able to upload his own data
(format information and examples are available on our
website [64]), which, after checking to ensure that the
format is correct, will be analyzed with our pipeline.
When data is submitted, DT-Web automatically
Figure 3 DT-Web DTI network view. A DTI network after applying our prediction pipeline. Each node represents a drug (blue heptagon) or a
target (gray circle), while each edge represents a drug-target interaction (user-provided ones in black, predictions in red).
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Figure 4 DT-Web Drug Combination Prediction Example. Once the user submits a list of genes, DT-Web calculates, using the pathways
stored in the database, a list of possible drugs that indirectly target such genes, using the pipeline described above. When finished, the user will
see a list of such drugs, ordered by direct and indirect targets, which can be filtered by selecting an appropriate combination of parameters
(either one or more drugs/targets). By selecting a drug or a target, the user will also view an excerpt of the pathway used by the algorithm to
compute the prediction. By clicking on a drug the user obtains a list of predicted targets.
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generates a temporary page (see Figure 2) that allows to
check the job status and, when ready, view results. To
avoid long waits, an e-mail address, where a notification
will be sent as soon as the results are available, can be
provided. When viewing predictions, the user can apply
filters based either on p-value or correlation by choosing
an appropriate threshold. He will also be able to down-
load a file containing all the results in text format, or
visualize a graphical representation of the resulting DTI
network (see Figure 3).
To take advantage of our multi-purpose pipeline, the
user can choose the “Drug Combination” job in the “Pre-
diction Tools” menu. There, he can run the enriched
analysis by indicating a set of indirectly influenced genes.
Once the analysis starts, DT-Web automatically gener-
ates a temporary page (see Figure 4) that allows to check
the job status and, if ready, view results. Once the analy-
sis is performed, the results page will show the list of
reachable targets and their interacting drugs. For each
drug-target pair the DT-Hybrid prediction score is shown
if the interaction does not come from a validated source.
A list of filters can be applied to the results. The list of
found drugs can be filtered by selecting only some of
them as well as the drug-target interaction type, validated
or predicted. Moreover, it is also possible to apply a filter
on the set of found targets. For each target and drug, the
user can visualize an interactive sub-network centered on
the given entity. Additional information is available by
clicking on the visualized elements, for example, the list
of residing pathways can be visualized by clicking on
each edge.
Use cases
Users access DT-Web via the web interface where drugs
and targets can be retrieved using a simple search
engine. Furthermore, users can provide their own data
to compute DTI predictions or simplify the early devel-
opment stages in drug combination or repositioning stu-
dies. The algorithm is also available for download under
Creative Commons license. This allows users to use
DT-Web for large-scale studies, not suitable for our web
environment. Examples illustrating our DTI prediction
and multi-purpose pipelines follow.
DT-Hybrid has been used, in connection with other
algorithms, to associate Simvastatin and Ketoconazole
drugs to breast cancer treatment [75]. Our multipurpose
pipeline, being a new software, has not yet been used
for the intended studies. That is why we used our meth-
odology to predict the combination of Propofol and
Sevoflurane whose additive action produces conscious-
ness and movement to skin incision during general
anesthesia [76]. Both drugs interact with the GABAA
receptor. Propofol is a potentiator of the b2 subunit
(GABRB2) of GABAA, while Sevoflurane is an agonist of
the a1 subunit (GABRA1) of GABAA with its binding
site between both subunits [77]. Probably is such a loca-
tion which hinders agonist activity, thereby producing
mutually substitutable actions [78].
Conclusions
The prediction of novel drug-target interactions is a fun-
damental process in order to reduce the costly and time-
consuming phases of drug discovery and design. As a
matter of fact, knowing the possible unknown effects on
the proteome of a drug can be extremely useful in under-
standing its true potential or predicting side effects.
Other studies, such as drug repositioning, drug combi-
nations or substitutions, help to eliminate the need to
develop new drugs. Drug repositioning studies exploit
existing drug for new purposes that go beyond the origi-
nal ones, while drug combination studies try to modify
or intensify the overall effect of two or more drugs by
administering them together. Similarly, drug substitu-
tions studies try to replace drugs having significant side
effects with others aiming to reduce them. For this pur-
pose, a tool that guides the early stages of the experi-
mental process can significantly reduce the time and
costs associated therewith.
This is the context of DT-Web. Its main goal is to
provide a simple system that allows a user to quickly
browse predictions of probable novel DTI, to produce
new ones from their own data, or to simplify the experi-
mental studies described above. All this by using a data-
base obtained combining a new valuable resource DT-
Hybrid with data extracted from Drug-Bank and
PathwayCommons. Finally, all the results can be down-
loaded in text format or viewed on-line through the
help of interactive graphical interfaces that simplify their
understanding.
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